Please assess the completion status of the following clinical trial:

Trial Title: Biological Therapy in Treating Women With Stage IV Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Phase I:~* Histologically confirmed infiltrating ductal carcinoma of the breast~* Metastatic disease~  * Clinically asymptomatic with non-life-threatening metastases allowed~* Measurable or evaluable disease by radiograph, CT scan, MRI, nuclear medicine bone scan, or physical examination~  * No measurable disease allowed if tumor or metastasis has been removed or successfully treated prior to study~* No rapidly progressive symptomatic disease affecting major organ systems (e.g., lungs and liver)~* Stable or unstable disease for 3 months on hormonal therapy~* Stable or unstable disease for at least 1 month after chemotherapy~* No active brain metastases~  * Brain metastases previously treated with definitive radiotherapy and/or surgical resection allowed~* Hormone receptor status:~  * Estrogen and progesterone receptor status known~Phase II:~* All Phase I criteria~* HER2/neu overexpression (2+ or 3+) by immunohistochemistry~  * Prior trastuzumab (Herceptin) allowed if disease still overexpresses HER2/neu~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Karnofsky 70-100% OR~* ECOG 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 50,000/mm\^3~* Hemoglobin at least 8 g/dL~Hepatic:~* Bilirubin less than 1.5 times normal~* SGOT less than 1.5 times normal~Renal:~* Creatinine no greater than 1.8 mg/dL~* Creatinine clearance at least 60 mL/min~* BUN no greater than 1.5 times normal~Cardiovascular:~* No myocardial infarction within the past year~* No prior myocardial infarction with coronary symptoms requiring medication and/or depressed left ventricular function (LVEF less than 50% by MUGA)~* No angina or coronary symptoms requiring medication and/or with depressed left ventricular function (LVEF less than 50% by MUGA)~* No congestive heart failure requiring medical management~* LVEF at least 50% at rest by MUGA~* No uncontrolled hypertension (i.e., systolic blood pressure \[BP\] ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg)~Pulmonary:~* FEV1, DLCO, and FVC at least 50% predicted~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No other serious medical or psychiatric illness that would preclude study participation~* No other prior or concurrent malignancy within the past 5 years except curatively treated squamous cell carcinoma in situ of the cervix, basal cell skin cancer, or any other curatively treated disease in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* Prior trastuzumab allowed for phase I~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy~Endocrine therapy:~* See Disease Characteristics~* Concurrent hormonal therapy for breast cancer must continue during study~* No other concurrent hormonal therapy except steroids for adrenal failure, septic shock, or pulmonary toxicity or hormonal therapy for non-disease-related conditions (e.g., insulin for diabetes)~Radiotherapy:~* See Disease Characteristics~Surgery:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Aldesleukin, Sargramostim & therapeutic autologous lymphocytes (Type: EXPERIMENTAL): Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.

Based on this trial design, predict the completion outcome and termination type (if applicable).